Phase 2 Cardiomyopathy Trial, Recruiting NCT05511246 Sponsor: The Methodist Hospital Research Institute Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT05511246
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman between 18 and 85 years old who already has an implanted defibrillator (ICD) device in your chest
  • You have been diagnosed with heart damage caused by a previous heart attack, confirmed by heart tests or imaging
  • You have had one of the following in the last 6 months: at least 3 episodes of a fast, dangerous heart rhythm (VT) treated by your ICD or medication; at least 1 shock from your ICD; at least 3 VT episodes within a single 24-hour period; or a sustained dangerous heart rhythm that your ICD did not detect, recorded on a heart monitor or ECG
  • Your doctors have decided you are a suitable candidate for a procedure called radiofrequency (RF) ablation to treat your dangerous heart rhythm
  • You are able and willing to attend all required appointments before, during, and after the trial
  • You are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • Your kidneys are not working well enough, based on specific blood or urine test results (confirm with trial site)
  • Your heart's pumping ability is very severely reduced (ejection fraction of 10% or below)
  • A blood clot has been found inside your heart's main pumping chamber on an ultrasound scan
  • Doctors are unable to safely access the main pumping chamber of your heart through your blood vessels
  • You have a condition that is likely to reduce your life expectancy to less than 12 months
  • You have the most severe level of heart failure symptoms (meaning you feel breathless or unwell even at complete rest)
  • You have had heart surgery in the past 2 months (unless your dangerous heart rhythm was constant and uncontrolled)
  • You have had an acute heart attack or serious heart artery problem in the past 2 months, confirmed by specific heart tests
  • Your dangerous heart rhythm is being caused by something that can be fixed, such as an imbalance in your body's salts or a medication side effect
  • You have severe narrowing of the aortic heart valve, or a severely leaking mitral heart valve
  • You are pregnant
  • You are unwilling or unable to sign the consent form
  • You have tested positive for COVID-19 within 14 days of the trial procedure
  • You are currently enrolled in, or planning to join, another research study at the same time as this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Miguel Valderrabano, MD, The Methodist Hospital Research Institute

Phone: 7134416548

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The Methodist Hospital Research Institute
Registry
ClinicalTrials.gov
Start date
12 April 2023
Est. completion
12 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Ventricular tachycardia recurrence; Hospitalization for cardiac causes; Severe procedural complications; Death

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov